The global cancer biologics market is projected to grow from USD 117.45 billion in 2025 to USD 221.43 billion by 2034, expanding at a CAGR of 7.30%. Growth is driven by rising cancer prevalence, innovative biotechnological developments, and increasing adoption of targeted biologic treatments across major healthcare systems.
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
3.1. Market Snapshot
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
5.1. COVID-19 Landscape: Cancer Biologics Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
8.1. Cancer Biologics Market, by Drug Class
8.1.1 Monoclonal Antibodies
8.1.1.1. Market Revenue and Forecast
8.1.2. Cancer Growth Inhibitors
8.1.2.1. Market Revenue and Forecast
8.1.3. Vaccines
8.1.3.1. Market Revenue and Forecast
8.1.4. Recombinants Proteins
8.1.4.1. Market Revenue and Forecast
8.1.5. CAR-T Cells
8.1.5.1. Market Revenue and Forecast
8.1.6. Angiogenesis Inhibitors
8.1.6.1. Market Revenue and Forecast
8.1.7. Interleukins (IL)
8.1.7.1. Market Revenue and Forecast
8.1.8. Interferons (IFN)
8.1.8.1. Market Revenue and Forecast
8.1.9. Gene Therapy
8.1.9.1. Market Revenue and Forecast
8.1.10. Others
8.1.10.1. Market Revenue and Forecast
9.1. Cancer Biologics Market, by Applications
9.1.1. Blood Cancer
9.1.1.1. Market Revenue and Forecast
9.1.2. Lung Cancer
9.1.2.1. Market Revenue and Forecast
9.1.3. Breast Cancer
9.1.3.1. Market Revenue and Forecast
9.1.4. Colorectal Cancer
9.1.4.1. Market Revenue and Forecast
9.1.5. Prostate Cancer
9.1.5.1. Market Revenue and Forecast
9.1.6. Gastric Cancer
9.1.6.1. Market Revenue and Forecast
9.1.7. Ovarian Cancer
9.1.7.1. Market Revenue and Forecast
9.1.8. Skin Cancer
9.1.8.1. Market Revenue and Forecast
9.1.9. Liver Cancer
9.1.9.1. Market Revenue and Forecast
9.1.10. Others
9.1.10.1. Market Revenue and Forecast
10.1. Cancer Biologics Market, by End use
10.1.1. Hospitals
10.1.1.1. Market Revenue and Forecast
10.1.2. Cancer Center
10.1.2.1. Market Revenue and Forecast
10.1.3. Academics & Research Institutes
10.1.3.1. Market Revenue and Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Drug Class
11.1.2. Market Revenue and Forecast, by Applications
11.1.3. Market Revenue and Forecast, by End use
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Drug Class
11.1.4.2. Market Revenue and Forecast, by Applications
11.1.4.3. Market Revenue and Forecast, by End use
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Drug Class
11.1.5.2. Market Revenue and Forecast, by Applications
11.1.5.3. Market Revenue and Forecast, by End use
11.2. Europe
11.2.1. Market Revenue and Forecast, by Drug Class
11.2.2. Market Revenue and Forecast, by Applications
11.2.3. Market Revenue and Forecast, by End use
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Drug Class
11.2.4.2. Market Revenue and Forecast, by Applications
11.2.4.3. Market Revenue and Forecast, by End use
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Drug Class
11.2.5.2. Market Revenue and Forecast, by Applications
11.2.5.3. Market Revenue and Forecast, by End use
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Drug Class
11.2.6.2. Market Revenue and Forecast, by Applications
11.2.6.3. Market Revenue and Forecast, by End use
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Drug Class
11.2.7.2. Market Revenue and Forecast, by Applications
11.2.7.3. Market Revenue and Forecast, by End use
11.3. APAC
11.3.1. Market Revenue and Forecast, by Drug Class
11.3.2. Market Revenue and Forecast, by Applications
11.3.3. Market Revenue and Forecast, by End use
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Drug Class
11.3.4.2. Market Revenue and Forecast, by Applications
11.3.4.3. Market Revenue and Forecast, by End use
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Drug Class
11.3.5.2. Market Revenue and Forecast, by Applications
11.3.5.3. Market Revenue and Forecast, by End use
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Drug Class
11.3.6.2. Market Revenue and Forecast, by Applications
11.3.6.3. Market Revenue and Forecast, by End use
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Drug Class
11.3.7.2. Market Revenue and Forecast, by Applications
11.3.7.3. Market Revenue and Forecast, by End use
11.4. MEA
11.4.1. Market Revenue and Forecast, by Drug Class
11.4.2. Market Revenue and Forecast, by Applications
11.4.3. Market Revenue and Forecast, by End use
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Drug Class
11.4.4.2. Market Revenue and Forecast, by Applications
11.4.4.3. Market Revenue and Forecast, by End use
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Drug Class
11.4.5.2. Market Revenue and Forecast, by Applications
11.4.5.3. Market Revenue and Forecast, by End use
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Drug Class
11.4.6.2. Market Revenue and Forecast, by Applications
11.4.6.3. Market Revenue and Forecast, by End use
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Drug Class
11.4.7.2. Market Revenue and Forecast, by Applications
11.4.7.3. Market Revenue and Forecast, by End use
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Drug Class
11.5.2. Market Revenue and Forecast, by Applications
11.5.3. Market Revenue and Forecast, by End use
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Drug Class
11.5.4.2. Market Revenue and Forecast, by Applications
11.5.4.3. Market Revenue and Forecast, by End use
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Drug Class
11.5.5.2. Market Revenue and Forecast, by Applications
11.5.5.3. Market Revenue and Forecast, by End use
12.1. Abbott
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. Angel
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. Amgen, Inc
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. AstraZeneca
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. BioNTech
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Bristol-Mayer Squibb Company
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. Dr. Reddy's Laboratories
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. Duality Biologics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. Eli Lilly and Company
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. F.Hoffmann-La Roche Ltd.
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
14.1. About Us
14.2. Glossary of Terms
For questions or customization requests, please reach out to us at sales@precedenceresearch.com
Plan your call and get expert insights!
Schedule a Meeting
No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client
Get a Sample
Report Description
Get a Sample
Report Description